---
title: "A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease"
euct_id: 2024-515177-94-00
eudra_ct_number: 2022-001063-27
phase: Phase 4
status: Completed
sponsor: Cavion Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-515177-94-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-515177-94-00"
ctis_last_updated: "2025-11-07T02:33:14.336972613"
source: EU Clinical Trials Information System (CTIS)
---
# A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease

**EU CT Number:** [2024-515177-94-00](https://euclinicaltrials.eu/ctis-public/view/2024-515177-94-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Completed
- **Sponsor:** Cavion Inc.
- **Start Date:** 2022-12-01
- **Completion Date:** 2025-03-31
- **Conditions:** Parkinson's Disease
- **Interventions:** Placebo comprised of microcrystalline cellulose, used in JZP385-202-MCC placebo in the IMPD., JZP385

## Member States

Trial is authorized in 3 member states: Germany, Poland, Spain.

## Sites (17)

- Hospital Universitario De La Princesa, Madrid, Spain
- Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Asociacion Instituto De Investigacion Sanitaria Biobizkaia, Barakaldo, Spain
- Hospital Universitario Virgen De La Macarena, Sevilla, Spain
- Hospital Universitario Ramon Y Cajal, Madrid, Spain
- Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p., Lublin, Poland
- Neurologiczny NZOZ Centrum Leczenia SM Ośrodek Badań Klinicznych im. dr n. med. Hanki Hertmanowskiej, Katowice, Poland
- Wielospecjalistyczna Poradnia Lekarska Synapsis, Gdańsk, Poland
- Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k., Cracow, Poland
- Centrum Zdrowia I Urody Maxxmed, Lublin, Poland
- Etg Neuroscience Sp. z o.o., Warsaw, Poland
- Rivermed Sp. z o.o., Poznan, Poland
- DKD HELIOS Klinik Wiesbaden GmbH, Wiesbaden, Germany
- Pharmakologisches Studienzentrum Chemnitz GmbH, Chemnitz, Germany
- Velocity Clinical Research Germany GmbH, Wiesbaden, Germany
- Zentrum fuer klinische Forschung Dr. I. Schoell GmbH, Bad Homburg, Germany
- curiositas ad sanum Studien und Beratungs GmbH, Haag I.ob, Germany

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's Disease
Age groups: adults 18-64, elderly 65+
Sex: male, female

Period: Screening Period
This is up to 4 weeks. There is no treatment with IMP or placebo in this period.

Period: Treatment Period
This will consist of 17 weeks

Period: Safety Follow-up Visit
2 weeks after end of treatment
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-515177-94-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-515177-94-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-515177-94-00*